CCI 103F

Known as: CCI-103F 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1986-2013
01219862013

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
PURPOSE Pimonidazole HCl is widely used in immunohistochemical analyses of hypoxia in normal and malignant tissues. The present… (More)
Is this relevant?
2000
2000
PURPOSE Development of a double hypoxic cell marker assay, using the bioreductive nitroimidazole derivatives CCI-103F and… (More)
Is this relevant?
1997
1997
PURPOSE The purposes of this study were to assess sources of variation in the distribution of nitroimidazole-labeled hypoxic… (More)
Is this relevant?
1997
1997
BACKGROUND AND PURPOSE The error associated with using biopsy-based methods for assessing parameters reflective of the tumor… (More)
Is this relevant?
1994
1994
PURPOSE The purpose of this study was to identify the prevalence and distribution of hypoxic tumor cells in spontaneous canine… (More)
Is this relevant?
1994
1994
PURPOSE The purpose of this work was to evaluate multiple injections of CCI-103F, a marker of hypoxia, as a method to quantify… (More)
Is this relevant?
1994
1994
An enzyme-linked immunosorbent assay (ELISA) has been developed for measuring the in vivo binding of a hexafluorinated 2… (More)
  • table I
  • table II
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
1990
1990
Selective retention of hexafluoromisonidazole, CCI-103F, in RIF-1 and SCCVII tumours of C3H/Km mice has been measured by 1H/19F… (More)
Is this relevant?
1989
1989
We have evaluated two fluorinated misonidazole analogues, Ro 07-0741 and CCI-103F, as potential probes for the non-invasive… (More)
Is this relevant?
1986
1986
A hexafluorinated 2-nitroimidazole (CCI-103F) has been synthesized and its properties as a hypoxic cell binder investigated. The… (More)
Is this relevant?